Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
Optimizing JC and BK polyomavirus IgG testing for seroepidemiology and patient counseling
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 4390943
Author(s) Kardas, Piotr; Leboeuf, Céline; Hirsch, Hans H.
Author(s) at UniBasel Hirsch, Hans H.
Year 2015
Title Optimizing JC and BK polyomavirus IgG testing for seroepidemiology and patient counseling
Journal Journal of Clinical Virology
Volume 71
Pages / Article-Number 28-33
Keywords Antibodies, Viral/*blood; BK Virus/*immunology; Counseling; Diagnostic Errors; Enzyme-Linked Immunosorbent Assay/methods; Humans; Immunoglobulin G/*blood; JC Virus/*immunology; Polyomavirus Infections/*diagnosis/virology; Risk Assessment; Sensitivity and Specificity; Serologic Tests/*methods; Tumor Virus Infections/*diagnosis/virology; Antibody; BK virus; Cystitis; Elisa; JC virus; Multiple sclerosis; Natalizumab; Nephropathy; Pml; Polyomavirus; Screening; Transplantation
Mesh terms Antibodies, Viral, blood; BK Virus, immunology; Counseling; Diagnostic Errors; Enzyme-Linked Immunosorbent Assay, methods; Humans; Immunoglobulin G, blood; JC Virus, immunology; Polyomavirus Infections, virology; Risk Assessment; Sensitivity and Specificity; Serologic Tests, methods; Tumor Virus Infections, virology
Abstract BACKGROUND: Polyomavirus JC (JCPyV) and BK (BKPyV) can cause significant diseases in immunocompromised patients including nephropathy, hemorrhagic cystitis, and leukoencephalopathy. Recently, JCPyV and BKPyV IgG have been explored as risk predictors in multiple sclerosis and transplant patients, but sensitivity, specificity and quantification issues limit current performance. OBJECTIVE: To improve JCPyV and BKPyV-specific antibody testing. STUDY DESIGN: Healthy blood donor sera (N=400) were tested at dilutions 1:100, 1:200, and 1:400 for JCPyV- and BKPyV-specific IgG using VP1 virus-like particle (VLP)-based ELISAs normalized to a laboratory reference serum. Normalized optical density 492nm greater or equal 0.1 in all 3 dilutions was regarded as reactive. Sera with discordant reactivity in at least one dilution were retested after VLP preadsorption. RESULTS: At dilutions 1:100, 1:200, and 1:400, IgG reactivity was 74%, 60% and 53% for JCPyV, and 93%, 86% and 74% for BKPyV, respectively. At these dilutions, JCPyV-VLP preadsorption identified 56, 4 and 0 false-positives and 0, 4 and 27 false-negatives, respectively. Dilution-dependent sensitivity was 100%, 98%, and 89%, and specificity 65, 98%, and 100%, respectively. For sera diluted 100-, 200-, and 400-fold, BKPyV-VLP preadsorption identified 28, 1 and 0 false-positives, and 0, 0 and 46 false-negatives, and sensitivity was 100%, 100%, 86%, and specificity 50%, 98%, 100%, respectively. CONCLUSION: For seroepidemiology studies, normalized JCPyV and BKPyV IgG ELISA at 1:200 serum dilution provides optimal sensitivity and specificity with the lowest false-positive and false-negative rate. For individual risk assessment, dilutions of 100, 200, and 400 combined with preadsorption for low-reactive sera may be most appropriate.
Publisher ELSEVIER SCIENCE BV
ISSN/ISBN 1873-5967 (Electronic) 1386-6532 (Linking)
URL https://www.ncbi.nlm.nih.gov/pubmed/26370311
edoc-URL https://edoc.unibas.ch/61901/
Full Text on edoc No
Digital Object Identifier DOI 10.1016/j.jcv.2015.07.305
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/26370311
ISI-Number WOS:000361145400005
Document type (ISI) Journal Article
 
   

MCSS v5.8 PRO. 0.354 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
11/05/2024